Cross-protective peptide vaccine against influenza a viruses developed in HLA-A*2402 human immunity model

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Ichihashi, Toru ^a   Yoshida, Reiko ^a   Sugimoto, Chihiro ^a   Takada, Ayato ^a   Kajino, Kiichi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLPHENYLALANYLLEUCYLPROLYLTRYPTOPHANYLHISTIDYLARGINYLLEUCYLPHENYLALANINE; ARGINYLTYROSYLTHREONYLLYSYLTHREONYLTHREONYLTYROSYLTRYPTOPHANYLTRYPTOPHAN; CPG OLIGODEOXYNUCLEOTIDE; CYSTYLPHENYLALANYLMETHIONYLTYROSYLSERYLASPARTYLPHENYLALANYLHISTIDYLPHENYLALANINE; EPITOPE; HLA A ANTIGEN; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LEUCYLTRYPTOPHANYLISOLEUCYLLEUCYLASPARTYLARGINYLLEUCYLPHENYLALANYLPHENYLALANINE; MATRIX PROTEIN; METHIONYLTYROSYLGLUTAMINYLLYSYLLYSYLCYSTEINYLCYSTEINYLTHREONYLLEUCYLPHENYLALANINE; NEUTRALIZING ANTIBODY; PEPTIDE VACCINE; POLYINOSINIC POLYCYTIDYLIC ACID; SERYLPHENYLALANYLSERYLPHENYLALANYLGLYCYLGLYCYLPHENYLALANYLTHREONYLPHENYLALANINE; SERYLTYROSYLISOLEUCYLASPARAGINYLARGINYLTHREONYLGLYCYLTHREONYLPHENYLALANINE; SERYLTYROSYLLEUCYLISOLEUCYLARGINYLALANYLTHREONYLLEUCINE; THREONYLTYROSYLGLUTAMINYLTRYPTOPHANYLISOLEUCYLISOLEUCYLARGINYLASPARAGINYLTRYPTOPHAN; THREONYLTYROSYLPHENYLALANYLGLUTAMYLLYSYLVALYLGLUTAMYLARGINYLLEUCINE; TYROSYLTYROSYLLEUCYLGLUTAMYLLYSYLALANYLASPARAGINYLLYSYLISOLEUCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; HEMAGGLUTININ, HUMAN INFLUENZA A VIRUS; HLA A*24:02 ANTIGEN; HLA A24 ANTIGEN; HLA-A*24:02 ANTIGEN; SIALIDASE; SUBUNIT VACCINE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; AVIAN INFLUENZA; BIOINFORMATICS; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG ADMINISTRATION ROUTE; GENETIC CONSERVATION; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VIVO STUDY; INFLUENZA A; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; TRANSGENIC MOUSE; VIRAL CLEARANCE; VIRUS INHIBITION; VIRUS STRAIN; ANIMAL; CD8+ T LYMPHOCYTE; CROSS PROTECTION; ENZYMOLOGY; GENETICS; HUMAN; IMMUNOLOGY; INFLUENZA VIRUS A; LUNG; PATHOGENICITY; REPRODUCIBILITY; TIME; VACCINATION; VIROLOGY;

AVES; INFLUENZA A VIRUS; MUS; MUS MUSCULUS; ORTHOMYXOVIRIDAE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CROSS PROTECTION; EPITOPES; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HLA-A24 ANTIGEN; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; LUNG; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; NEURAMINIDASE; REPRODUCIBILITY OF RESULTS; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; VACCINATION; VACCINES, SUBUNIT;

EID: 80052891501     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024626     Document Type: Article

References (50)

1. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, et al. (2003) Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 115: 63-73.
2. Cox NJ, Subbarao K, (1999) Influenza. Lancet 354: 1277-1282.
3. Takada A, Shimizu Y, Kida H, (1994) Protection of mice against Aujeszky's disease virus infection by intranasal vaccination with inactivated virus. J Vet Med Sci 56: 633-637.
4. Takada A, Kida H, (1996) Protective immune response of chickens against Newcastle disease, induced by the intranasal vaccination with inactivated virus. Vet Microbiol 50: 17-25.
5. Ada GL, Jones PD, (1986) The immune response to influenza infection. Curr Top Microbiol Immunol 128: 1-54.
6. Fiore AE, Bridges CB, Cox NJ, (2009) Seasonal influenza vaccines. Curr Top Microbiol Immunol 333: 43-82.
7. Nichol KL, (2008) Efficacy and effectiveness of influenza vaccination. Vaccine 26: D17-22.
8. Alsharifi M, Furuya Y, Bowden TR, Lobigs M, Koskinen A, et al. (2009) Intranasal flu vaccine protective against seasonal and H5N1 avian influenza infections. PLoS One 4: e5336 Epub 2009 Apr 5329.
9. Bender BS, Croghan T, Zhang L, Small PA Jr, (1992) Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med 175: 1143-1145.
10. McMichael AJ, Gotch FM, Noble GR, Beare PA, (1983) Cytotoxic T-cell immunity to influenza. N Engl J Med 309: 13-17.
11. Zweerink HJ, Courtneidge SA, Skehel JJ, Crumpton MJ, Askonas BA, (1977) Cytotoxic T cells kill influenza virus infected cells but do not distinguish between serologically distinct type A viruses. Nature 267: 354-356.
12. Kees U, Krammer PH, (1984) Most influenza A virus-specific memory cytotoxic T lymphocytes react with antigenic epitopes associated with internal virus determinants. J Exp Med 159: 365-377.
13. Townsend AR, Skehel JJ, (1984) The influenza A virus nucleoprotein gene controls the induction of both subtype specific and cross-reactive cytotoxic T cells. J Exp Med 160: 552-563.
14. Gotch F, McMichael A, Smith G, Moss B, (1987) Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J Exp Med 165: 408-416.
15. Yap KL, Ada GL, McKenzie IF, (1978) Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 273: 238-239.
16. Yap KL, Ada GL, (1978) The recovery of mice from influenza virus infection: adoptive transfer of immunity with immune T lymphocytes. Scand J Immunol 7: 389-397.
17. Wells MA, Ennis FA, Albrecht P, (1981) Recovery from a viral respiratory infection. II. Passive transfer of immune spleen cells to mice with influenza pneumonia. J Immunol 126: 1042-1046.
18. Lukacher AE, Braciale VL, Braciale TJ, (1984) In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J Exp Med 160: 814-826.
19. Liang S, Mozdzanowska K, Palladino G, Gerhard W, (1994) Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J Immunol 152: 1653-1661.
20. Seo SH, Peiris M, Webster RG, (2002) Protective cross-reactive cellular immunity to lethal A/Goose/Guangdong/1/96-like H5N1 influenza virus is correlated with the proportion of pulmonary CD8(+) T cells expressing gamma interferon. J Virol 76: 4886-4890.
21. Seo SH, Webster RG, (2001) Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets. J Virol 75: 2516-2525.
22. Kreijtz JH, Bodewes R, van Amerongen G, Kuiken T, Fouchier RA, et al. (2007) Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25: 612-620 Epub 2006 Sep 2007.
23. Purcell AW, McCluskey J, Rossjohn J, (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6: 404-414.
24. Buus S, Lauemoller SL, Worning P, Kesmir C, Frimurer T, et al. (2003) Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. Tissue Antigens 62: 378-384.
25. Nielsen M, Lundegaard C, Worning P, Lauemoller SL, Lamberth K, et al. (2003) Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 12: 1007-1017.
26. Nielsen M, Lundegaard C, Worning P, Hvid CS, Lamberth K, et al. (2004) Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach. Bioinformatics 20: 1388-1397 Epub 2004 Feb 1312.
27. Larsen MV, Lundegaard C, Lamberth K, Buus S, Brunak S, et al. (2005) An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. Eur J Immunol 35: 2295-2303.
28. Sette A, Sidney J, (1999) Nine major HLA class I supertypes account for the vast preponderance of HLA-A and-B polymorphism. Immunogenetics 50: 201-212.
29. Nagata T, Toyota T, Ishigaki H, Ichihashi T, Kajino K, et al. (2007) Peptides coupled to the surface of a kind of liposome protect infection of influenza viruses. Vaccine 25: 4914-4921 Epub 2007 Apr 4920.
30. Taneichi M, Ishida H, Kajino K, Ogasawara K, Tanaka Y, et al. (2006) Antigen chemically coupled to the surface of liposomes are cross-presented to CD8+ T cells and induce potent antitumor immunity. J Immunol 177: 2324-2330.
31. Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H, (2003) Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 21: 3212-3218.
32. Nakano Y, Mori M, Nishinohara S, Takita Y, Naito S, et al. (2001) Surface-linked liposomal antigen induces IgE-selective unresponsiveness regardless of the lipid components of liposomes. Bioconjug Chem 12: 391-395.
33. Nakano Y, Mori M, Nishinohara S, Takita Y, Naito S, et al. (1999) Antigen-specific, IgE-selective unresponsiveness induced by antigen-liposome conjugates. Comparison of four different conjugation methods for the coupling of antigen to liposome. Int Arch Allergy Immunol 120: 199-208.
34. Naruse H, Ogasawara K, Kaneda R, Hatakeyama S, Itoh T, et al. (1994) A potential peptide vaccine against two different strains of influenza virus isolated at intervals of about 10 years. Proc Natl Acad Sci U S A 91: 9588-9592.
35. Belyakov IM, Ahlers JD, Brandwein BY, Earl P, Kelsall BL, et al. (1998) The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. J Clin Invest 102: 2072-2081.
36. Kos FJ, Mullbacher A, (1992) Enhancement of antigen-specific activation of CD8+ memory cytotoxic T cells by B cell-derived factors. Immunobiology 186: 410-420.
37. Liu Y, Mullbacher A, (1989) Activated B cells can deliver help for the in vitro generation of antiviral cytotoxic T cells. Proc Natl Acad Sci U S A 86: 4629-4633.
38. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC, (2006) Cell-mediated protection in influenza infection. Emerg Infect Dis 12: 48-54.
39. Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, et al. (1999) Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 5: 2756-2765.
40. Gohara R, Imai N, Rikimaru T, Yamada A, Hida N, et al. (2002) Phase 1 clinical study of cyclophilin B peptide vaccine for patients with lung cancer. J Immunother 25: 439-444.
41. Doherty PC, Allan W, Boyle DB, Coupar BE, Andrew ME, (1989) Recombinant vaccinia viruses and the development of immunization strategies using influenza virus. J Infect Dis 159: 1119-1122.
42. Lin YL, Askonas BA, (1981) Biological properties of an influenza A virus-specific killer T cell clone. Inhibition of virus replication in vivo and induction of delayed-type hypersensitivity reactions. J Exp Med 154: 225-234.
43. Flynn KJ, Belz GT, Altman JD, Ahmed R, Woodland DL, et al. (1998) Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 8: 683-691.
44. O'Neill E, Krauss SL, Riberdy JM, Webster RG, Woodland DL, (2000) Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. J Gen Virol 81: 2689-2696.
45. Kreijtz JH, de Mutsert G, van Baalen CA, Fouchier RA, Osterhaus AD, et al. (2008) Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 82: 5161-5166 Epub 2008 Mar 5119.
46. La Gruta NL, Kedzierska K, Pang K, Webby R, Davenport M, et al. (2006) A virus-specific CD8+ T cell immunodominance hierarchy determined by antigen dose and precursor frequencies. Proc Natl Acad Sci U S A 103: 994-999 Epub 2006 Jan 2017.
47. Ely KH, Cookenham T, Roberts AD, Woodland DL, (2006) Memory T cellpopulations in the lung airways are maintained by continual recruitment. J Immunol 176: 537-543.
48. Day EB, Zeng W, Doherty PC, Jackson DC, Kedzierska K, et al. (2007) The context of epitope presentation can influence functional quality of recalled influenza A virus-specific memory CD8+ T cells. J Immunol United States pp. 2187-2194.
49. Deliyannis G, Jackson DC, Ede NJ, Zeng W, Hourdakis I, et al. (2002) Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J Virol 76: 4212-4221.
50. Deliyannis G, Kedzierska K, Lau YF, Zeng W, Turner SJ, et al. (2006) Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur J Immunol 36: 770-778.